Not currently recruiting at UC Irvine
Efficacy and Safety of Losmapimod in Treating Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) (Reach)
Summary
- Eligibility
- for people ages 18-65 (full criteria)
- Location
- at Irvine, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Fulcrum Therapeutics
- ID
- NCT05397470
- Phase
- Phase 3 Facioscapulohumeral Muscular Dystrophy Research Study
- Study Type
- Interventional
- Participants
- Expecting 230 study participants
- Last Updated